Alto Partners, a private equity firm, completed the acquisition of 40% of Diatech Pharmacogenetics, a developer of pharmacogenetics tests specialized in cancer precision medicine. Diatech, founded in 1998 by Fabio Biondi and headquartered in Jesi is a provider of diagnostic solutions and reagents in the pharmacogenetics and pharmacogenomics sectors. The company provides customized genomic testing solutions in the oncological disease niche, aimed at optimizing cancer treatment effectiveness through increased diagnosis precision.